Global Scientific Program Manager Agilent Technologies
The early stages of drug discovery suffer from high failure rates, with only 5% of compounds making it to lead generation stage. For this reason, there is a need to generate more insightful data earlier to inform better decision-making, accelerate research and increase the pace of drug discovery.
Many workflows have adopted multiplex assays as they allow simultaneous measurement of many targets from a single sample volume. However, these multiplex assays involve many steps, making them hard to automate, require a specific proprietary instrument to run and are not able to operate easily at high-throughputs.
This presentation will introduce a solution to the difficulties encountered when trying to implement multiplex assays in the context of drug discovery and biomarker screening. It will explain the formats that are available and demonstrate how automation-friendly, no wash multiplex assays can best be used to improve the efficiency of high-throughput drug and biomarker discovery pipelines, increasing the number of drugs that you can take to market.
.jpg "Paul Wylie photo")
